U.S. markets open in 30 minutes
  • S&P Futures

    3,914.00
    -8.50 (-0.22%)
     
  • Dow Futures

    31,949.00
    +33.00 (+0.10%)
     
  • Nasdaq Futures

    13,217.50
    -84.50 (-0.64%)
     
  • Russell 2000 Futures

    2,288.30
    +3.20 (+0.14%)
     
  • Crude Oil

    63.28
    +0.06 (+0.09%)
     
  • Gold

    1,782.60
    -15.30 (-0.85%)
     
  • Silver

    27.99
    +0.06 (+0.20%)
     
  • EUR/USD

    1.2214
    +0.0046 (+0.38%)
     
  • 10-Yr Bond

    1.4410
    +0.0520 (+3.74%)
     
  • Vix

    22.42
    -0.69 (-2.99%)
     
  • GBP/USD

    1.4141
    -0.0000 (-0.00%)
     
  • USD/JPY

    106.1700
    +0.2880 (+0.27%)
     
  • BTC-USD

    51,326.84
    +519.32 (+1.02%)
     
  • CMC Crypto 200

    1,025.86
    +31.20 (+3.14%)
     
  • FTSE 100

    6,686.12
    +27.15 (+0.41%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Neuronetics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Neuronetics
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Chief Financial Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020.

A pre-recorded webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.

Investor Contact:

Mark R. Klausner
Westwicke Partners
443-213-0501
ir@neuronetics.com

Media Contact:

Meagan Dominic
Vault Communications
610-455-2779
mdominick@vaultcommunications.com